HSD3B1 mediated anti-androgen resistance in prostate cancer requires specific androgen precursors

被引：0
|
作者：
Armstrong, Cameron M. [1 ]
Liu, Chengfei [1 ]
Lou, Wei [1 ]
Lombard, Alan P. [1 ]
Evans, Christopher [1 ]
Gao, Allen C. [1 ]
机构：
[1] Univ Calif Davis, Med Ctr, Sacramento, CA 95817 USA
来源：
CANCER RESEARCH | 2019年 / 79卷 / 13期
关键词：
D O I：
10.1158/1538-7445.SABCS18-3030
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3030
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Galectin-3 Is Implicated in Tumor Progression and Resistance to Anti-androgen Drug Through Regulation of Androgen Receptor Signaling in Prostate Cancer
    Dondoo, Tsogt-Ochir
    Fukumori, Tomoharu
    Daizumoto, Kei
    Fukawa, Tomoya
    Kohzuki, Miho
    Kowada, Minoru
    Kusuhara, Yoshito
    Mori, Hidehisa
    Nakatsuji, Hiroyoshi
    Takahashi, Masayuki
    Kanayama, Hiro-Omi
    ANTICANCER RESEARCH, 2017, 37 (01) : 125 - 134
  • [32] Cancer-associated fibroblast-secreted glucosamine alters the androgen biosynthesis program in prostate cancer via HSD3B1 upregulation
    Cui, Di
    Li, Jianneng
    Zhu, Ziqi
    Berk, Michael
    Hardaway, Aimalie
    McManus, Jeffrey
    Chung, Yoon-Mi
    Alyamani, Mohammad
    Valle, Shelley
    Tiwari, Ritika
    Han, Bangmin
    Goudarzi, Maryam
    Willard, Belinda
    Sharifi, Nima
    JOURNAL OF CLINICAL INVESTIGATION, 2023, 133 (07):
  • [33] HSD3B1, prostate cancer mortality and modifiable outcomes
    Freitas, Pedro F. S.
    Abdshah, Alireza
    McKay, Rana R.
    Sharifi, Nima
    NATURE REVIEWS UROLOGY, 2024,
  • [34] Association of Missense Polymorphism in HSD3B1 With Outcomes Among Men With Prostate Cancer Treated With Androgen-Deprivation Therapy or Abiraterone
    Shiota, Masaki
    Narita, Shintaro
    Akamatsu, Shusuke
    Fujimoto, Naohiro
    Sumiyoshi, Takayuki
    Fujiwara, Maki
    Uchiumi, Takeshi
    Habuchi, Tomonori
    Ogawa, Osamu
    Eto, Masatoshi
    JAMA NETWORK OPEN, 2019, 2 (02) : e190115
  • [35] Missense polymorphism in HSD3B1 in Japanese men treated with primary androgen-deprivation therapy for metastatic prostate cancer.
    Shiota, Masaki
    Fujimoto, Naohiro
    Imada, Kenjiro
    Kashiwagi, Eiji
    Takeuchi, Ario
    Inokuchi, Junichi
    Tatsugami, Katsunori
    Kajioka, Shunichi
    Eto, Masatoshi
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [36] Prostate cancer risk after anti-androgen treatment for priapism
    Tabitha Goetz
    Arthur L. Burnett
    International Urology and Nephrology, 2014, 46 : 757 - 760
  • [37] Androgen Metabolism and Severe Asthma: HSD3B1 Genotype Identifies Glucocorticoid Responsiveness
    Gaston, B. M.
    Sharifi, N.
    Bazeley, P.
    Deboer, M.
    Bleecker, E. R.
    Meyers, D. A.
    Comhair, S. A.
    Marozkina, N.
    Cotton, C.
    Noel, P.
    Mauger, D.
    Levy, B. D.
    Israel, E.
    Castro, M.
    Moore, W. C.
    Peters, S. P.
    Busse, W. W.
    Teague, W.
    Wenzel, S. E.
    Fitzpatrick, A. M.
    Fahy, J. V.
    Calhoun, W. J.
    Erzurum, S. C.
    Chung, K. F.
    Zein, J. G.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2020, 201
  • [38] Androgen receptor-mediated upregulation of quaking affects androgen receptor-related prostate cancer development and anti-androgen receptor therapy
    Zhang, Keke
    Yan, Fei
    Lei, Xiaoying
    Wei, Di
    Lu, Huanyu
    Zhu, Zheng
    Xiang, An
    Ye, Zichen
    Wang, Li
    Zheng, Wanxiang
    Li, Xi'an
    Yuan, Jiarui
    Lu, Zifan
    Yuan, Jianlin
    MOLECULAR MEDICINE REPORTS, 2018, 17 (06) : 8203 - 8211
  • [39] Clinical impact of HSD3B1 polymorphism by metastatic volume and somatic HSD3B1 alterations in advanced prostate cancer
    Shiota, Masaki
    Fujimoto, Naohiro
    Sekino, Yohei
    Tsukahara, Shigehiro
    Nagakawa, Shohei
    Takamatsu, Dai
    Abe, Tatsuro
    Kinoshita, Fumio
    Ueda, Shohei
    Ushijima, Miho
    Matsumoto, Takashi
    Kashiwagi, Eiji
    Inokuchi, Junichi
    Uchiumi, Takeshi
    Oda, Yoshinao
    Eto, Masatoshi
    ANDROLOGIA, 2022, 54 (01)
  • [40] Prostate cancer risk after anti-androgen treatment for priapism
    Goetz, Tabitha
    Burnett, Arthur L.
    INTERNATIONAL UROLOGY AND NEPHROLOGY, 2014, 46 (04) : 757 - 760
12345